85 results
6-K
EX-99.1
ALVO
Alvotech
22 May 24
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
6:30am
to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
9:00am
, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
8:41am
to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries
6-K
EX-99.1
ALVO
Alvotech
30 Apr 24
Current report (foreign)
8:00am
reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South
6-K
EX-99.1
ALVO
Alvotech
25 Apr 24
Current report (foreign)
12:36pm
expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle
6-K
EX-99.1
1zmf9nnqyrf 49i8n
19 Apr 24
Current report (foreign)
8:05am
6-K
EX-99.1
504 iatcnx08o3vtwm
16 Apr 24
Current report (foreign)
6:30pm
6-K
EX-99.1
r1q1 ne5y1s9c83w
22 Mar 24
Alvotech Announces Increase in Number of Own Shares
4:15pm
6-K
EX-99.1
4k2dgn1p42r2mjf
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.1
3rpl6ls83y6iww7 9k
1 Mar 24
Alvotech Appoints Interim Chief Quality Officer
12:16pm
6-K
EX-99.1
nsuwy0g76dlrpumfx
26 Feb 24
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
7:00am
6-K
EX-99.1
jhtq97jp bbr72tl0
23 Feb 24
Current report (foreign)
8:39pm
6-K
EX-99.1
r514z275jogh
15 Feb 24
Current report (foreign)
4:00pm
6-K
EX-99.1
em1y238j79s4uqrl7js8
29 Jan 24
Current report (foreign)
7:00am
6-K
EX-99.1
usyn2dbpfof7fy3jzjef
19 Jan 24
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
4:00pm
6-K
EX-99.1
o4ny56gvz3fya
10 Jan 24
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
7:00am
6-K
EX-99.1
x7sgq9
3 Jan 24
Current report (foreign)
2:28pm
6-K/A
EX-99.1
pra11t98 s6l
30 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
9:19am
6-K
EX-99.1
bijlzfm
29 Nov 23
Current report (foreign)
7:00am
6-K
EX-99.1
wkqroab70l3nrekf
29 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
7:00am